GLP-1 medications face increased regulatory scrutiny in India and Japan

Regulators in India and Japan are increasing oversight of GLP-1 receptor agonists due to concerns regarding inappropriate use and illegal distribution. In India, the central government has instructed states and union territories to enhance monitoring of how these weight-loss medications are promoted and distributed. Minister of State for Health Anupriya Patel stated that these drugs are approved for treating Type 2 diabetes and managing chronic weight in specific patients, requiring prescriptions from specialists like endocrinologists.

The Central Drugs Standard Control Organisation issued advisories to prevent misleading advertising and to ensure drugs are sold only through authorized channels. Regulators have been directed to monitor digital platforms for surrogate promotional content and to act against the diversion of medications into unregulated markets.

In Japan, concerns have been raised regarding the medical and regulatory appropriateness of GLP-1 use. Reports indicate the illegal resale of tirzepatide, originally prescribed for Type 2 diabetes under insurance, for cosmetic weight loss. An editorial in Diabetology International highlighted the risks of inappropriate use, including the acquisition of drugs through unofficial channels and online prescriptions, which can lead to severe health consequences such as ketosis and ketoacidosis.